PBYI Q3 2025 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54M-32.4% YoY

Gross Profit

$42M77.7% margin

Operating Income

$10M17.6% margin

Net Income

$9M16.2% margin

EPS (Diluted)

$0.17

QoQ Revenue Growth

+3.9%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$10M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$203M

Total Liabilities

$88M

Stockholders' Equity

$115M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$81M	-32.4%
Gross Profit	$42M	$51M	-17.8%
Operating Income	$10M	$22M	-56.6%
Net Income	$9M	$20M	-56.5%

Revenue Segments

Product

$52M95%

Royalty

$3M5%